摘要：这3名患者在取得稳定的分子学缓解之后（融合基因转阴PCRU）停用达沙替尼。1名患者复发，另外两名患者在1年后仍保持了PCRU。以前说过，达沙替尼确实可以提高免疫力，希望今后能获得更多的相关研究报告。
+ ]; w5 A- _- E8 t 关于这个研究值得注意的是，这三名患者都是服用格列卫失败后转用达沙替尼的，也即他们对格列卫是耐药的。这与法国的格列卫停药研究又有所不同，那个研究中的患者都是对格列卫反应良好的。希望医生们能扩大研究长期观察，看看停用达沙替尼是否能持久不复发。( O. X! p8 t; F' _4 w" S
" \, d5 y4 k7 D/ x. r" k作者：来自澳大利亚+ W; K& G5 m) M- f
来源：Haematologica. 2011.8.9.
# R4 _6 j' R) v# {0 V7 d9 \Dear Group,7 ~* _$ v' Z. _0 ?, K) C7 h
+ ?0 N5 b% ^' c4 z o
Some of you are on Dasatinib (Sprycel) and we wish to give news on all CML- I; X# C+ E% s: H8 Z' {1 l
therapies. Here is a report from Australia on 3 patients who went off Sprycel
7 w) W3 F. u6 W% S) Yafter stable molecular response (PCRU). 1 patient relapsed but 2/3 patients
/ H1 } b w1 N5 b7 Premain in stable PCRU at the 1 year mark. Some of you may remember that Sprycel
( z( N6 \+ X& U0 Gdoes spike up the immune system so I hope more reports come out on this issue.' u& S+ b; b. p- {' p. @
, K3 O2 g' O8 n& E+ I W$ P( bThe remarkable news about Sprycel cessation is that all 3 patients had failed' G' |1 m% `! D) Q) `
Gleevec and Sprycel was their second TKI so they had resistant disease. This is
6 h( [* C8 ~" {% b% t" q1 fdifferent from the stopping Gleevec trial in France which only targets patients
" z/ V5 o$ S- O+ P6 w6 w: pwho have done well on Gleevec.
) L. y/ X# J% T* O' D" Z# D: F8 U* F1 H4 Z% L: q" n
Hopefully, the doctors will report on a larger study and long-term to see if the
( ~* q, b( c; Z, [2 e0 `response off Sprycel is sustained.2 @8 K0 R6 e& `) l+ {& k2 ]4 Y
7 T$ \! X+ p$ m1 U, N1 Y/ X7 c1 ^& rBest Wishes,& I3 R! X- X, P% t
Anjana
6 S- y6 m, {% ]* V% E! Q- z4 @ d: M! B) l. E( ?
3 {# ^! C8 B' H& I
8 r& j, e( d+ v" `/ [( }
Haematologica. 2011 Aug 9. [Epub ahead of print]# F( x1 c# p. E; P( `2 C
Durable complete molecular remission of chronic myeloid leukemia following
( @( e+ f, p$ Y5 t1 Q Hdasatinib cessation, despite adverse disease features.) z5 ^' {. ^: z6 T1 U
Ross DM, Bartley PA, Goyne J, Morley AA, Seymour JF, Grigg AP.$ S/ k5 w7 t7 n; B, O+ m
Source& `$ a! m: D: O9 N
Adelaide, Australia; V% M8 h N2 {6 g8 Q+ E S
0 \6 F; G1 q1 S" b0 _5 Q, p) D OAbstract
' o- H0 Q1 Z+ \; JPatients with chronic myeloid leukemia, treated with imatinib, who have a6 e& o$ I. ?8 X. {$ `6 G
durable complete molecular response might remain in CMR after stopping$ T M% j" ~' @* I
treatment. Previous reports of patients stopping treatment in complete molecular. d. x( g7 `" R1 X+ c) k
response have included only patients with a good response to imatinib. We6 z- ^8 v$ x: R! E: I2 n
describe three patients with stable complete molecular response on dasatinib: W: \9 n0 g0 [. I. T- ]% }
treatment following imatinib failure. Two of the three patients remain in( p& l! D# V* R9 a" P
complete molecular response more than 12 months after stopping dasatinib. In
3 p! [0 t( m0 g+ E* }these two patients we used highly sensitive patient-specific BCR-ABL1 DNA PCR to! h5 ~9 R* p% i% c: B6 d
show that the leukemic clone remains detectable, as we have previously shown in
3 y u2 h6 w8 w( s! ]imatinib-treated patients. Dasatinib-associated immunological phenomena, such as0 n1 p2 r" x) j3 t. @6 e4 L5 l% F
the emergence of clonal T cell populations, were observed both in one patient
/ {! ~7 }2 x/ W; T5 Cwho relapsed and in one patient in remission. Our results suggest that the
8 Z& ?, U6 {: t" c% G( Pcharacteristics of complete molecular response on dasatinib treatment may be8 \* @) E5 U, p( P
similar to that achieved with imatinib, at least in patients with adverse6 D( d! J+ h5 X$ F8 ^/ i
disease features.
3 r9 L' t( @3 U0 S9 C |
显身卡
